More recently ALK inhibitors have entered clinical development and remarkably clinical efficacy has been observed in NSCLC patients harbouring EML4-ALK translocations.     ///    The biology and treatment of EML4-ALK non-small cell lung cancer..     ///    EML4-ALK is oncogenic both in vitro and in vivo and ALK kinase inhibitors are quite effective in pre-clinical model systems.     ///    EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features.     ///    "This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC.. "